Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
EXExact Sciences Corporation logo

Exact Sciences Corporation (EXAS)

NASDAQ Capital Market · Currency in USD
$104.91 ▲ +0.00 (+0.00%)
At close: Mar 23, 9:30 AM ET. Market closed.

Summary

Previous Close
$104.91
Open
$104.91
Day's Range
$104.91 – $104.91
52 Week Range
$38.81 – $104.98
Volume
21,562,141
Avg. Volume
2,533,730
Market Cap
$20.03B
Beta (5Y Monthly)
1.44
PE Ratio (TTM)
--
EPS (TTM)
-$0.56
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$92.95

Profile: Exact Sciences Corporation

Sector
Healthcare
Industry
Medical - Diagnostics & Research
Full-time employees
6,900
CEO
Kevin T. Conroy

Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers.

Earnings

DateEst.Actual
Feb 13, 2026-$0.11-$0.45Miss
Nov 3, 2025-$0.06$0.24Beat
Aug 6, 2025-$0.02$0.22Beat
May 1, 2025-$0.37-$0.54Miss
Feb 19, 2025-$0.29-$0.06Beat
Nov 5, 2024-$0.20-$0.21Miss

Analyst view

Consensus price target
$92.95 ▼ -11.4%
Range $46.00 – $135.00
Rating: Buy
Buy 54% · Hold 41% · Sell 5%

Get free alerts on EXAS and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.